Idiopathic pulmonary fibrosis (IPF) is a progressive-fibrosing lung disease with a median survival of less than 5 years. Currently, two agents, pirfenidone and nintedanib are approved for this disease, and both have been shown to reduce the rate of decline in lung function in patients with IPF. However, both have significant adverse effects and neither completely arrest the decline in lung function. Thirty experimental agents with unique mechanisms of action that are being evaluated for the treatment of IPF are discussed. These agents work through various mechanisms of action, these include inhibition of transcription nuclear factor k-B on fibroblasts, reduced expression of metalloproteinase 7, the generation of more lysophosphatidic acids, blocking the effects of transforming growth factor ß, and reducing reactive oxygen species as examples of some unique mechanisms of action of these agents. New drug development has the potential to expand the treatment options available in the treatment of IPF patients. It is expected that the adverse drug effect profiles will be more favorable than current agents. It is further anticipated that these new agents or combinations of agents will arrest the fibrosis, not just slow the fibrotic process.
28 September 2018 in Baylor University Medical Center Proceedings
Immune thrombocytopenic purpura (ITP) is an acquired thrombocytopenia where autoantibodies are generated against platelet antigens. Primary ITP is often idiopathic, whereas secondary ITP has many potential causes, including drug induced, infection related (human immunodeficiency virus, hepatitis C), leukemias, or autoimmune such as systemic lupus erythematosus. ITP is a common cause of thrombocytopenia in asymptomatic individuals, where evidence of bleeding may be minor or absent. Chronic silent bleeding leading to extreme anemia in patients with ITP is rare, and evidence of multiorgan damage is even rarer; hence the relevance of this case report. Here we describe a case of primary ITP with severe chronic blood loss leading to profound anemia causing renal failure and a type II non-ST elevation myocardial infarction. Our patient underwent extensive workup for the etiology of both thrombocytopenia and anemia and was eventually treated with packed red blood cell and platelet transfusions, along with intravenous steroids and immunoglobulin therapy.
Selecting donor organs is both a science and an art. The calculus is often complex evaluating recipients’ acute needs and the quality and risks of the donor organs. Sarcoidosis is usually a disease of exclusion and considered an idiopathic inflammatory granulomatous process frequently in the lung but often with multiorgan involvement. New insights into the interplay between the environmental or occupational antigens and the susceptible genetic host in sarcoidosis have come to light. One such occupational antigen with mixed data regarding the risk of developing sarcoidosis after exposure is silica dust. Despite strict exposure limitations enforced in the United States and several other governing bodies worldwide, clusters of silicosis are on the rise due to engineered stone (quartz), which contain silica particles that when cut can create a dust that can exceed exposure limitations. Data on the quartz-sarcoidosis relationship is minimal, and thus questions exist regarding the risk of silica dust exposure and the risk of sarcoidosis. Silicosis tends to only affect the lungs, preventing them usually from being transplanted while sarcoidosis is recognized as having a high probability of multiple organ involvement. An index case discovered during organ recovery highlights the possible association between silica exposure and sarcoidosis. This case also examples the complexity of donor organ evaluation and the challenges in organ procurement from exposed individuals.